CompletedInterventionalPhase 1Phase 2Updated Mar 30, 2020
Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution | NCT01001195 | Trialant
CompletedInterventionalPhase 2Updated Oct 18, 2013
Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution
ClinicalTrials.gov ID
NCT01001195
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
165Actual
Last Update Posted
Oct 18, 2013Estimated
Start Date
Nov 2009
Primary Completion Date
Apr 2010Actual
Completion Date
Apr 2010Actual
Brief Summary
This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).
Glaucoma, Open-Angle
Ocular Hypertension
AGN-210669 ophthalmic solution, 0.1%
AGN-210669 ophthalmic solution, 0.075%
AGN-210669 ophthalmic solution, 0.05%
bimatoprost ophthalmic solution 0.03%
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ocular hypertension or primary open-angle glaucoma in each eye
Patient requires IOP lowering medication in each eye
Exclusion Criteria:
Ocular hyperemia or other ocular surface findings in either eye
Active ocular disease
Current or anticipated use of any topical ocular medication (including artificial tears) during the study
Intraocular surgery within past six months or unilateral cataract surgery.
Functionally significant visual field loss
Anticipated wearing of contact lenses during study
Use of other medications that affect IOP such as glaucoma treating medications, within 2 months of screening visit